Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133415 | 0.91 | ALDH1A1 (0.39) | ADORA2AADORA1TP53 | |
| SCHEMBL6133517 | 0.91 | ADORA2A (0.38) | ADORA2AADORA1TP53 | |
| SCHEMBL6134002 | 0.90 | ADORA2A (0.37) | ADORA2AADORA1TP53SMN1; SMN2 | |
| SCHEMBL6133319 | 0.89 | ADORA2A (0.43) | ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL6133311 | 0.88 | ADORA2A (0.38) | ADORA2AADORA1TP53 | |
| SCHEMBL6133849 | 0.87 | ADORA2A (0.38) | RECQLADORA2AADORA1KDM4ESMN1; SMN2 | |
| SCHEMBL6133677 | 0.86 | ADORA2A (0.40) | ADORA2AADORA1TP53 | |
| SCHEMBL6133772 | 0.86 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL6133969 | 0.84 | MGMT (0.41) | ADORA2AADORA1 | |
| SCHEMBL6134581 | 0.84 | ADORA2A (0.40) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | RECQL 45/4885HCRTR1 2971/4885HCRTR2 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.